"Open communication with executive level leadership is encouraged & appreciated. Work-life balance is recognized & applauded. People treat one another like family with a sense of pride about ...

Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Merz. The announcement ...

It is administered through intramuscular, intradermal and subcutaneous routes. Merz Therapeutics, a subsidiary of Merz Pharma GmbH & Co KgaA, focuses on developing and distributing therapeutic ...

Merz Therapeutics, with North American headquarters in Raleigh, has gained a new use for Xeomin, its botulinum toxin therapy. The U.S. Food and Drug Administration approved Merz’s supplemental ...

Xeomin, a botulinum toxin therapy developed by Raleigh-based Merz Therapeutics, has gained yet another new use. The U.S. Food and Drug Administration approved Merz’s supplemental Biologics License ...

FRANKFURT, Germany--(BUSINESS WIRE)-- Merz Therapeutics, a company of the Merz Group and a leader in the field of neurotoxins, is expanding its strategic partnership with Vensica Therapeutics as ...

Incobotulinumtoxin A is under clinical development by Merz Therapeutics and currently in Phase II for Unspecified Musculoskeletal Disorders. According to GlobalData, Phase II drugs for Unspecified ...